BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35872581)

  • 1. [Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome].
    Zhao AL; Li M; Li LF; Gan XA; Wang J; Li H; Shen K; Yang YF; Niu T
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2173-2180. PubMed ID: 35872581
    [No Abstract]   [Full Text] [Related]  

  • 2. Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.
    Zhao A; Yang J; Li M; Li L; Gan X; Wang J; Li H; Shen K; Yang Y; Niu T
    Front Immunol; 2022; 13():882589. PubMed ID: 35479073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    He Y; Gao Y; Ping L; He H; Huang C; Bai B; Wang X; Li Z; Cai Q; Huang Y; Pan X; Zeng W; Liu Y; Huang H
    J Cancer Res Clin Oncol; 2023 May; 149(5):2017-2027. PubMed ID: 35809114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.
    Han L; Li L; Wu J; Li X; Zhang L; Wang X; Fu X; Ma W; Sun Z; Zhang X; Chang Y; Guo S; Zhang M
    Leuk Lymphoma; 2014 Sep; 55(9):2048-55. PubMed ID: 24359240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Jin Z; Wang Y; Wang J; Wu L; Pei R; Lai W; Wang Z
    Hematology; 2018 May; 23(4):228-234. PubMed ID: 28982299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.
    Li N; Jiang M; Wu WC; Zhou HJ; Zou LQ
    Hematology; 2022 Dec; 27(1):909-916. PubMed ID: 35993333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma.
    Li N; Zhang L; Liu J; Zhang J; Weng HW; Zhuo HY; Zou LQ
    Cancer Biol Ther; 2017 Apr; 18(4):252-256. PubMed ID: 28278074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome.
    Jia J; Song Y; Lin N; Liu W; Ping L; Zheng W; Wang X; Xie Y; Tu M; Zhang C; Ying Z; Deng L; Ding N; Zhu J
    Ann Hematol; 2016 Dec; 95(12):2023-2031. PubMed ID: 27595760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
    Zou H; He L; Hue Z; Liu M; Yao S; Zhu Y; Wang Z; Wang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8521-8533. PubMed ID: 37093345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
    Song Y; Yin Q; Wang J; Wang Z
    Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China.
    Li F; Li P; Zhang R; Yang G; Ji D; Huang X; Xu Q; Wei Y; Rao J; Huang R; Chen G
    Med Oncol; 2014 Apr; 31(4):902. PubMed ID: 24610542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lymphocyte function by IFN-γ secretion capability assay in the diagnosis of lymphoma-associated hemophagocytic syndrome.
    Hou H; Luo Y; Wang F; Yu J; Li D; Sun Z
    Hum Immunol; 2019 Dec; 80(12):1006-1011. PubMed ID: 31540793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma associated hemophagocytic syndrome: A single-center retrospective study.
    Chang Y; Cui M; Fu X; Han L; Zhang L; Li L; Li X; Sun Z; Wu J; Zhang X; Li Z; Nan F; Yan J; Sheng G; Zhang M
    Oncol Lett; 2018 Jul; 16(1):1275-1284. PubMed ID: 30061947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concentration of miR-133 is a useful marker for the diagnosis of lymphoma- associated hemophagocytic syndrome.
    Li W; Zhong Y; Shuang Y; Huang H; Huang Y; Yu L; Huang X
    Cancer Biomark; 2017 Aug; 20(2):159-164. PubMed ID: 28869447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Liu YZ; Bi LQ; Chang GL; Guo Y; Sun S
    Cancer Manag Res; 2019; 11():997-1002. PubMed ID: 30774427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study.
    Sano H; Kobayashi R; Tanaka J; Hashino S; Ota S; Torimoto Y; Kakinoki Y; Yamamoto S; Kurosawa M; Hatakeyama N; Haseyama Y; Sakai H; Sato K; Fukuhara T
    Br J Haematol; 2014 Jun; 165(6):786-92. PubMed ID: 24606577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome.
    Yao S; Jin Z; He L; Zhang R; Liu M; Hua Z; Wang Z; Wang Y
    Front Oncol; 2021; 11():788056. PubMed ID: 34938663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
    Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy of Programmed Cell Death Ligand 1 Antibody in Treatment of Extranodal Natural Killer/T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis.
    Yang CL; Chen X; Zhou HJ; Wu WC; Zou LQ
    J Hematol; 2024 Apr; 13(1-2):46-51. PubMed ID: 38644986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.